Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach

被引:304
|
作者
McIntyre, Roger S. [1 ,2 ,3 ,4 ]
Filteau, Marie-Josee [5 ,6 ,7 ]
Martin, Lawrence [8 ]
Patry, Simon [5 ,9 ]
Carvalho, Andre [2 ,10 ]
Cha, Danielle S. [1 ,2 ]
Barakat, maxime [11 ]
Miguelez, Maia [11 ]
机构
[1] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[2] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON M5T 2S8, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[4] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[5] Univ Laval, Dept Psychiat, Quebec City, PQ, Canada
[6] Univ Laval, Robert Giffard Res Ctr, Quebec City, PQ, Canada
[7] Clin Marie Fitzbach, Quebec City, PQ, Canada
[8] McMaster Univ, Dept Psychiat, Hamilton, ON, Canada
[9] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada
[10] Univ Fed Ceara, Psychiat Res Grp, Fac Med, Fortaleza, Ceara, Brazil
[11] Bristol Myers Squibb Canada, Montreal, PQ, Canada
关键词
Major depressive disorder; Treatment-resistant depression (TRD); Atypical antipsychotics; Augmentation; Combination; Lithium; CANMAT CLINICAL GUIDELINES; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DEEP BRAIN-STIMULATION; DOUBLE-BLIND; CANADIAN NETWORK; NEUROSTIMULATION THERAPIES; ANTIDEPRESSANT RESPONSE; MOOD DISORDERS;
D O I
10.1016/j.jad.2013.10.043
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Most adults with major depressive disorder (MDD) fail to achieve remission with index pharmacological treatment. Moreover, at least half will not achieve and sustain remission following multiple pharmacological approaches. Herein, we succinctly review treatment modalities proven effective in treatment-resistant depression (TRD). Methods: We conducted a review of computerized databases (PubMed, Google Scholar) from 1980 to April 2013. Articles selected for review were based on author consensus, adequacy of sample size, the use of a standardized experimental procedure, validated assessment measures and overall manuscript quality. Results: The evidence base supporting augmentation of conventional antidepressants with atypical antipsychotics (i.e., aripiprazole, quetiapine, and olanzapine) is the most extensive and rigorous of all pharmacological approaches in TRD. Emerging evidence supports the use of some psychostimulants (i.e., lisdexamfetamine) as well as aerobic exercise. In addition, treatments informed by pathogenetic disease models provide preliminary evidence for the efficacy of immune-inflammatory based therapies and metabolic interventions. Manual based psychotherapies remain a treatment option, with the most compelling evidence for cognitive behavioral therapy. Disparate neurostimulation strategies are also available for individuals insufficiently responsive to pharmacotherapy and/or psychosocial interventions. Limitations: Compared to non-treatment-resistant depression, TRD has been less studied. Most clinical studies on TRD have focused on pharmacotherapy-resistant depression, with relatively fewer studies evaluating "next choice" treatments in individuals who do not initially respond to psychosocial and/or neurostimulatory treatments. Conclusion: The pathoetiological heterogeneity of MDD/TRD invites the need for mechanistically dissimilar, and empirically validated, treatment approaches for TRD. (C) 2013 Elsevier By. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] Treatment-resistant depression: state of the art Part II. Treatment
    Luchini, Federica
    Cosentino, Luca
    Pensabene, Laura
    Mauri, Mauro
    Lattanzi, Lorenzo
    RIVISTA DI PSICHIATRIA, 2014, 49 (06) : 228 - 240
  • [22] Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
    Zhou, Xinyu
    Keitner, Gabor I.
    Qin, Bin
    Ravindran, Arun V.
    Bauer, Michael
    Del Giovane, Cinzia
    Zhao, Jingping
    Liu, Yiyun
    Fang, Yiru
    Zhang, Yuqing
    Xie, Peng
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (11)
  • [23] A register-based approach to identifying treatment-resistant depression-Comparison with clinical definitions
    Hagg, David
    Brenner, Philip
    Reutfors, Johan
    Li, Gang
    DiBernardo, Allitia
    Boden, Robert
    Brandt, Lena
    PLOS ONE, 2020, 15 (07):
  • [24] Management of Treatment-Resistant Depression
    Keitner, Gabor I.
    Mansfield, Abigail K.
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2012, 35 (01) : 249 - +
  • [25] How best to manage treatment-resistant depression?
    Hicks, Paul
    Hicks, Ximena Prieto
    Meyer, Heidi
    Shisslak, Catherine
    JOURNAL OF FAMILY PRACTICE, 2010, 59 (09) : 490 - 497
  • [26] Pharmacological Treatments for Patients with Treatment-Resistant Depression
    Ruberto, Valerie L.
    Jha, Manish K.
    Murrough, James W.
    PHARMACEUTICALS, 2020, 13 (06) : 2 - 23
  • [27] Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression
    Cantu, Filippo
    Ciappolino, Valentina
    Enrico, Paolo
    Moltrasio, Chiara
    Delvecchio, Giuseppe
    Brambilla, Paolo
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 280 : 45 - 53
  • [28] Management of Treatment-Resistant Depression in Children and Adolescents
    DeFilippis, Melissa
    Wagner, Karen Dineen
    PEDIATRIC DRUGS, 2014, 16 (05) : 353 - 361
  • [29] Treatment-Resistant Depression in Poland-Epidemiology and Treatment
    Galecki, Piotr
    Samochowiec, Jerzy
    Mikulowska, Magdalena
    Szulc, Agata
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
  • [30] Management of Treatment-Resistant Depression: Challenges and Strategies
    Voineskos, Daphne
    Daskalakis, Zafiris J.
    Blumberger, Daniel M.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 221 - 234